A Study to Provide Access to Trabectedin in Patients With Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment .
Verified by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., April 2008